Cullinan Therapeutics (CGEM) Competitors $5.90 +0.15 (+2.61%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.90 +0.00 (+0.08%) As of 10/3/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. SDGR, JANX, COGT, GPCR, ABCL, TLRY, PHVS, RCUS, EVO, and AMPHShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Schrodinger (SDGR), Janux Therapeutics (JANX), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), AbCellera Biologics (ABCL), Tilray Brands (TLRY), Pharvaris (PHVS), Arcus Biosciences (RCUS), Evotec (EVO), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Schrodinger Janux Therapeutics Cogent Biosciences Structure Therapeutics AbCellera Biologics Tilray Brands Pharvaris Arcus Biosciences Evotec Amphastar Pharmaceuticals Schrodinger (NASDAQ:SDGR) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Which has stronger earnings & valuation, SDGR or CGEM? Cullinan Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$237.92M6.37-$187.12M-$2.48-8.30Cullinan TherapeuticsN/AN/A-$167.38M-$3.23-1.83 Does the media favor SDGR or CGEM? In the previous week, Schrodinger had 9 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 9 mentions for Schrodinger and 0 mentions for Cullinan Therapeutics. Schrodinger's average media sentiment score of 0.57 beat Cullinan Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media. Company Overall Sentiment Schrodinger Positive Cullinan Therapeutics Neutral Do analysts rate SDGR or CGEM? Schrodinger presently has a consensus target price of $26.57, suggesting a potential upside of 29.05%. Cullinan Therapeutics has a consensus target price of $26.00, suggesting a potential upside of 340.68%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has more risk and volatility, SDGR or CGEM? Schrodinger has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Do insiders & institutionals hold more shares of SDGR or CGEM? 79.1% of Schrodinger shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 21.0% of Schrodinger shares are held by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is SDGR or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Cullinan Therapeutics' return on equity of -36.56% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Cullinan Therapeutics N/A -36.56%-34.82% SummaryCullinan Therapeutics beats Schrodinger on 8 of the 15 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$339.68M$3.33B$6.09B$10.56BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-1.8322.1478.0526.71Price / SalesN/A416.27577.76178.61Price / CashN/A47.2037.7961.25Price / Book0.589.9312.556.56Net Income-$167.38M-$52.80M$3.31B$277.70M7 Day Performance-1.01%5.22%4.28%2.41%1 Month Performance-14.62%13.01%7.85%9.30%1 Year Performance-63.89%25.18%71.37%31.22% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics2.172 of 5 stars$5.90+2.6%$26.00+340.7%-63.4%$339.68MN/A-1.8330SDGRSchrodinger3.2427 of 5 stars$19.72+1.4%$27.83+41.1%+18.1%$1.43B$207.54M-7.95790Analyst DowngradeJANXJanux Therapeutics2.5193 of 5 stars$23.51+0.3%$78.31+233.1%-45.7%$1.41B$10.59M-13.0630Positive NewsCOGTCogent Biosciences2.6695 of 5 stars$12.51+4.5%$20.00+59.9%+49.4%$1.36BN/A-7.0380GPCRStructure Therapeutics3.1285 of 5 stars$24.45+3.7%$75.71+209.7%-35.5%$1.36BN/A-23.29136ABCLAbCellera Biologics3.0481 of 5 stars$4.83+7.1%$8.00+65.6%+137.9%$1.35B$28.83M-8.78500News CoverageGap UpTLRYTilray Brands2.7362 of 5 stars$1.20-0.8%$1.94+61.5%-4.7%$1.33B$821.31M-0.522,842Upcoming EarningsGap UpPHVSPharvaris2.3215 of 5 stars$24.99-1.5%$34.00+36.1%+30.7%$1.33BN/A-7.4430Positive NewsGap DownRCUSArcus Biosciences1.8001 of 5 stars$12.53+1.1%$21.14+68.7%-12.8%$1.32B$258M-3.95500EVOEvotec1.6234 of 5 stars$3.75+3.0%$5.40+44.0%+19.3%$1.29B$862.40M0.004,827High Trading VolumeAMPHAmphastar Pharmaceuticals4.4569 of 5 stars$27.89+0.9%$31.60+13.3%-42.2%$1.29B$731.97M10.452,028Positive News Related Companies and Tools Related Companies SDGR Alternatives JANX Alternatives COGT Alternatives GPCR Alternatives ABCL Alternatives TLRY Alternatives PHVS Alternatives RCUS Alternatives EVO Alternatives AMPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
